- Pfizer Inc (NYSE:PFE) has dosed the first participants in Phase 1 clinical trial to evaluate a single dose quadrivalent mRNA vaccine against influenza in healthy adults.
- Also Read: Moderna Puts Its First Seasonal Flu Vaccine In The Clinic
- Pfizer’s mRNA influenza vaccine program is the first in a planned wave of programs leveraging mRNA technology for influenza.
- Beyond influenza, the Company plans to explore mRNA in other respiratory viruses.
- The Phase 1 randomized study will evaluate the safety, tolerability, and immunogenicity of a single dose of an influenza mRNA vaccine in healthy adults 65-85 years of age, with an FDA-approved standard quadrivalent influenza vaccine as a control.
- In 2018, Pfizer collaborated with BioNTech SE (NASDAQ:BNTX), under which Pfizer will carry out the clinical development and commercialization of mRNA-based influenza vaccines.
- Upon potential approval and commercialization, BioNTech would receive a royalty on Pfizer’s sales.
- Read Next: Sanofi, Translate Bio Initiate Early-Stage mRNA Influenza Vaccine Trial.
- Price Action: PFE stock is down 0.69% at $43.27 during the premarket session on the last check Tuesday.
Citigroup Maintains Neutral on Park Hotels & Resorts, Raises Price Target to $15
Citigroup analyst Smedes Rose maintains Park Hotels & Resorts (NYSE:PK) with a Neutral and raises the price target from $13 to $15.
